In the clinic, conventional chemotherapy is widely used to treat patients with KRAS-mutant NSCLC, although chemotherapy plus immune checkpoint blockade has been recently approved as the first-line regimen for NSCLC, including patients with KRAS mutations (45, 46). Here, KRAS is linked to non-small cell lung carcinoma.